Stock HRMY HARMONY BIOSCIENCES HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
29.25 USD -0.24% Intraday chart for Harmony Biosciences Holdings, Inc. -0.34% -9.44%
04-11 Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy MT
04-03 Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms MT

Business Summary

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.

Number of employees: 246

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
438 100.0 % 582 100.0 % +32.93%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
438 100.0 % 582 100.0 % +32.93%

Managers

Managers TitleAgeSince
Jeffrey Dayno CEO
 Chief Executive Officer 66 31/10/17
Sandipkumar S. Kapadia DFI
 Director of Finance/CFO 53 28/03/21
David Bradshaw CTO
 Chief Tech/Sci/R&D Officer 62 -
Tricia Glover CMP
 Compliance Officer - -
Luis Sanay IRC
 Investor Relations Contact - 28/02/22
Cate McCanless PRN
 Corporate Officer/Principal - -
Audrey Murphy HRO
 Human Resources Officer - -
Sharon Goldbach PRN
 Corporate Officer/Principal - -
Ulrich Christian LAW
 General Counsel - 31/12/20
Andrew Serafin PRN
 Corporate Officer/Principal 49 31/08/17

Members of the board

Members of the board TitleAgeSince
Jeffrey Aronin FOU
 Founder 56 24/07/17
R. Graf BRD
 Director/Board Member 59 10/11/20
Andreas Wicki BRD
 Director/Board Member 64 31/08/17
Jack Nielsen BRD
 Director/Board Member 60 31/08/17
Gary Sender BRD
 Director/Board Member 62 31/07/20
Antonio Gracias BRD
 Director/Board Member 53 31/08/17
Peter E. Anastasiou BRD
 Director/Board Member 54 11-04
Juan Sabater BRD
 Director/Board Member 59 31/12/16
Jeffrey Dayno CEO
 Chief Executive Officer 66 31/10/17
Linda Szyper BRD
 Director/Board Member 58 17/11/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 56,791,214 33,312,251 ( 58.66 %) 0 58.66 %

Shareholders

NameEquities%Valuation
Valor Management LLC
19.76 %
11,218,033 19.76 % 377 M $
Marshman Fund Trust Ii
18.76 %
10,651,120 18.76 % 358 M $
BlackRock Advisors LLC
9.890 %
5,614,573 9.890 % 189 M $
Fidelity Management & Research Co. LLC
9.295 %
5,276,825 9.295 % 177 M $
Vanguard Fiduciary Trust Co.
6.473 %
3,674,764 6.473 % 123 M $
Vivo Capital LLC
4.591 %
2,606,247 4.591 % 88 M $
HBM Partners AG (Investment Management)
3.784 %
2,147,943 3.784 % 72 M $
STATE STREET CORPORATION
2.396 %
1,360,447 2.396 % 46 M $
Pacer Advisors, Inc.
2.158 %
1,224,910 2.158 % 41 M $
Morgan Stanley Investment Management, Inc.
1.913 %
1,086,215 1.913 % 36 M $

Company contact information

Harmony Biosciences Holdings, Inc.

630 West Germantown Pike Suite 215

19462, Plymouth Meeting

+

http://www.harmonybiosciences.com
address Harmony Biosciences Holdings, Inc.(HRMY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for Harmony Biosciences Holdings, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
29.25 USD
Average target price
41.5 USD
Spread / Average Target
+41.88%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HARMONY BIOSCIENCES HOLDINGS, INC. Stock Harmony Biosciences Holdings, Inc.
-9.44% 1.66B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 234B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 196B
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HRMY Stock
  4. Company Harmony Biosciences Holdings, Inc.